Mantle Cell Lymphoma (MCL) Clinical Trial
Official title:
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but this is the first time that they are being given together.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06043011 -
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
|
||
| Active, not recruiting |
NCT04477486 -
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT03571828 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
|
Phase 1 | |
| Terminated |
NCT02914938 -
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04049513 -
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
|
Phase 1 | |
| Recruiting |
NCT03869619 -
REal World Data in LYmphoma and Survival in Adults
|
||
| Active, not recruiting |
NCT04830137 -
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03547115 -
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
|
Phase 1 | |
| Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04767308 -
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
|
Early Phase 1 | |
| Active, not recruiting |
NCT02213926 -
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06464861 -
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT03265158 -
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
|
N/A | |
| Enrolling by invitation |
NCT04488354 -
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
|
Phase 1 | |
| Recruiting |
NCT05720052 -
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05716087 -
A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT02362035 -
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05406154 -
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
|
||
| Recruiting |
NCT05951959 -
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
|
Phase 2 |